Intuitive Surgical, Inc. (ISRG) Stock Forecasts

Argus analyst David H. Toung raised the price target for Intuitive Surgical, Inc. (ISRG) to $500. The company designs and markets da Vinci robotic surgical systems. Toung covers medical devices and healthcare services.

Original reporting
Published Oct 30, 2026, 7:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 8:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ISRG
Bullish
high confidence
Mentioned
$ISRG
Relevance
7/10
AlphAI data visualization · based on finance.yahoo.com
Decision brief

The 30-second read

$ISRGBullishMed
01

Why it matters

Analyst upgrade could attract new buying interest and support price.

02

Market read

Target raise may prompt short-term buying and influence sector sentiment.

03

What to watch

Regulatory approvals and reimbursement rates could constrain upside.

Relevance 7/10Novelty 6/10Timing: immediate after publication

Background

Intuitive Surgical designs and sells the da Vinci robotic surgical system.

Company-level read

Ticker impact

$ISRGBullishHigh confidence
Context

Analyst David H. Toung raises Intuitive Surgical's price target to $500.

Expected impact

upward pressure as investors price in higher valuation.

Evidence & confidence

Analyst upgrade with a specific $500 target signals strong growth expectations.

Market effects

May lift sentiment for the broader medical device sector.

Potential modest boost to US healthcare stocks.

Limited to investors tracking robotic surgery technology.

Counterpoint

Target may be overly optimistic given competitive pressures.

Key entities

  • Intuitive Surgical, Inc.

    Manufacturer of da Vinci robotic surgical systems.

  • David H. Toung

    Senior analyst covering medical devices at Argus.

Related articles

$ISRGMedAI 8/10

Intuitive’s US da Vinci procedure growth slows again

Intuitive Surgical reported Q3 revenue of $3.05B, up 22% YoY, with net income of $523M. U.S. da Vinci procedure growth slowed to 10%, the lowest since the pandemic. CEO David Rosa cited adoption challenges in benign general surgery. The company cut instrument prices to boost adoption in high-volume procedures, reducing near-term revenue per procedure. Intuitive adjusted its 2026 da Vinci procedure growth forecast to 14-15%.